US 10,537,590 B2 · Cyclic dinucleotide compounds

Abstract

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and R3 are defined as in claim 1, which have valuable pharmacological properties, particularly are modulators of STING.

Claims55

Dependent claims

A compound of formula I

wherein
R1 is selected from the group consisting of H, F, —O—C1-3alkyl and OH, and
R2 is H, or
R2 is —CH2— and R1 is —O—, forming together a —CH2—O— bridge, and
R3 is a purine nucleobase selected from the group consisting of purine, adenine, guanine, xanthine and hypoxanthine, connected through its N9 nitrogen,
or a salt thereof.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/716,720Filed 27 Sep 2017

Priority

EP 1619191930 Sep 2016

Published

US 2018/0092937 A15 Apr 2018

Granted

21 Jan 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 31/7084
Carbohydrates; Sugars; Derivatives thereof: compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide,…
A61K 31/7076
Containing condensed or non-condensed pyrimidines: containing purines, e.g. adenosine, adenylic acid
A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents

Abstract

Claims55

Dependent claims

A compound of formula I

wherein
R1 is selected from the group consisting of H, F, —O—C1-3alkyl and OH, and
R2 is H, or
R2 is —CH2— and R1 is —O—, forming together a —CH2—O— bridge, and
R3 is a purine nucleobase selected from the group consisting of purine, adenine, guanine, xanthine and hypoxanthine, connected through its N9 nitrogen,
or a salt thereof.

3 more elements

Dependencies are inferred from the claim text.

Cyclic dinucleotide compounds

Life of this patent

Abstract

Claims55

Cyclic dinucleotide compounds

Life of this patent

Abstract

Claims55